Constipation Drug Shows Unexpected Power to Slow Chronic Kidney Disease
Clinical trial of 150 patients reveals lubiprostone preserves kidney function by boosting gut bacteria that produce protective compounds, opening new treatment pathways.
A medication commonly used to treat constipation has demonstrated surprising potential to slow the progression of chronic kidney disease, according to results from a multicenter clinical trial in Japan. Researchers at Tohoku University Graduate School of Medicine found that lubiprostone helped preserve kidney function in patients with moderate chronic kidney disease (CKD), tracing the protective effect to changes in gut bacteria that increased production of spermidine, a compound linked to healthier cellular function. The discovery opens an entirely new avenue for treating a condition that affects hundreds of millions worldwide and often leads to dialysis.
The Phase II clinical trial, known as the LUBI-CKD TRIAL, enrolled 150 patients with moderate chronic kidney disease across nine medical institutions in Japan. Participants received either lubiprostone or a placebo, allowing scientists to compare how the treatment affected kidney function over time. The results showed that patients who received either 8 microgram or 16 microgram doses of lubiprostone experienced a slower decline in kidney function compared with those in the placebo group, with kidney performance measured using estimated glomerular filtration rate (eGFR), a widely used indicator of kidney health.
The research team discovered that the protective effect was dose-dependent, meaning higher doses were associated with greater benefits. The 16 microgram group showed particularly promising preservation of kidney function signals during the 24-week trial period. This finding was unexpected because lubiprostone was designed specifically to treat constipation, not kidney disease. The connection emerged from researchers' observation that constipation frequently accompanies CKD and their hypothesis that treating constipation might improve kidney function by addressing gut health.
Scientists traced the kidney protection to fundamental changes in the gut microbiome. Lubiprostone increased production of spermidine, a naturally occurring compound tied to healthier mitochondrial activity. Mitochondria serve as the power plants of cells, generating the energy needed for proper cellular function. The researchers found that improved mitochondrial function appears to help shield kidney tissue from the progressive damage that characterizes chronic kidney disease.
The discovery highlights the growing recognition of the 'gut kidney axis,' the complex relationship between intestinal bacteria and kidney health. People with CKD often experience constipation and imbalances in gut microbes, which can contribute to inflammation and the buildup of harmful compounds in the body. While current treatments can help slow kidney damage, there are still no approved medications that directly restore kidney function, making this research particularly significant for the millions of patients facing potential dialysis as their disease progresses.
